Clinical Trial Results:
            A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare  T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
    
|     Summary | |
|     EudraCT number | 2021-000343-53 | 
|     Trial protocol | NL DE BE ES IT HR | 
|     Global completion date | |
|     Paediatric regulatory details | |
|     Is the trial part of an agreed EMA paediatric investigation plan? | |
|     Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? | |
|     Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? | |
|     Results information | |
|     Results version number | v1(current) | 
|     This version publication date | 
                                    30 Dec 2023
                             | 
|     First version publication date | 
                                    30 Dec 2023
                             | 
|     Other versions | |
|     Summary report(s) | bmt-ctn-2002-abbrev-clinical-study-rept_synopsis | 
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.    
 
				
